Advertisement
SCNI vs VANI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCNI is a Buy and VANI is a Hold.
SCNI's RSI Indicator is staying in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 83 cases where SCNI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
SCNI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCNI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SCNI entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.049) is normal, around the industry mean (3.498). P/E Ratio (0.016) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SCNI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCNI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VANI in upward trend: price may jump up because it broke its lower Bollinger Band on November 03, 2026
VANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where VANI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VANI's RSI Indicator exited the oversold zone, 21 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where VANI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for VANI just turned positive on November 09, 2026. Looking at past instances where VANI's MACD turned positive, the stock continued to rise in 38 of 51 cases over the following month. The odds of a continued upward trend are 75%.
Following a +8.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where VANI advanced for three days, in 156 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VANI as a result. In 73 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The 50-day moving average for VANI moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VANI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for VANI entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.089) is normal, around the industry mean (3.498). P/E Ratio (-2.972) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. VANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SCNI | VANI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 12 | 100 | |
PRICE GROWTH RATING 1..100 | 97 | 74 | |
P/E GROWTH RATING 1..100 | 97 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SCNI's Valuation (50) in the Pharmaceuticals Major industry is in the same range as VANI (68) in the null industry. This means that SCNI’s stock grew similarly to VANI’s over the last 12 months.
SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VANI (100) in the null industry. This means that SCNI’s stock grew similarly to VANI’s over the last 12 months.
SCNI's SMR Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for VANI (100) in the null industry. This means that SCNI’s stock grew significantly faster than VANI’s over the last 12 months.
VANI's Price Growth Rating (74) in the null industry is in the same range as SCNI (97) in the Pharmaceuticals Major industry. This means that VANI’s stock grew similarly to SCNI’s over the last 12 months.
VANI's P/E Growth Rating (22) in the null industry is significantly better than the same rating for SCNI (97) in the Pharmaceuticals Major industry. This means that VANI’s stock grew significantly faster than SCNI’s over the last 12 months.
| SCNI | VANI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 77% |
| Momentum ODDS (%) | N/A | 1 day ago 81% |
| MACD ODDS (%) | N/A | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Advances ODDS (%) | N/A | 1 day ago 75% |
| Declines ODDS (%) | 6 days ago 90% | 25 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SCNI’s FA Score shows that 1 FA rating(s) are green while VANI’s FA Score has 1 green FA rating(s).
- SCNI’s FA Score: 1 green, 4 red.
- VANI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SCNI’s TA Score shows that 3 TA indicator(s) are bullish while VANI’s TA Score has 4 bullish TA indicator(s).
- SCNI’s TA Score: 3 bullish, 2 bearish.
- VANI’s TA Score: 4 bullish, 5 bearish.
Price Growth
SCNI (@Biotechnology) experienced а -2.49% price change this week, while VANI (@Biotechnology) price change was -1.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
Reported Earning Dates
VANI is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VANI and
Correlation & Price change
A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To VANI | 1D Price Change % | ||
|---|---|---|---|---|
| VANI | 100% | +5.14% | ||
| VTVT - VANI | 60% Loosely correlated | +0.71% | ||
| AZR - VANI | 37% Loosely correlated | -6.25% | ||
| NKTX - VANI | 37% Loosely correlated | -8.09% | ||
| AXSM - VANI | 36% Loosely correlated | +1.20% | ||
| SCNI - VANI | 34% Loosely correlated | +4.85% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMKL | 2.63 | 0.31 | +13.36% |
| Defiance Daily Target 2X Long AMKR ETF (AMKL) | |||
| JSML | 88.63 | 2.96 | +3.46% |
| Janus Henderson Small Cap Growth Alpha ETF (JSML) | |||
| IYJ | 160.16 | 4.73 | +3.04% |
| iShares U.S. Industrials ETF (IYJ) | |||
| NOWL | 3.44 | 0.06 | +1.78% |
| GraniteShares 2x Long NOW Daily ETF (NOWL) | |||
| CPNS | 28.27 | 0.17 | +0.60% |
| Calamos Nasdaq-100 Structured Alt Protection ETF - September (CPNS) | |||